2596386-23-9
2596386-23-9
Chemical Structure
Moxifloxacin-d4
Synonym(s): BAY 12-8039-d4 free base
- CAS No.: 2596386-23-9
- Formula:C21H20D4FN3O4
- Molecular Weight:405.46
IUPAC Name: 1-cyclopropyl-6-fluoro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl-5,5,7,7-d4)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
InChIKey: FABPRXSRWADJSP-OUFHMVITSA-N
SMILES: O=C(C1=C2C(OC)=C(C(F)=C1)N3C([2H])([2H])[C@@]4([H])NCCC[C@]4(C3([2H])[2H])[H])C(C(O)=O)=CN2C5CC5
Biological Activity: Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Moxifloxacin-d4 | 99.9% | Moxifloxacin-d4 is the deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin (Standard) | 99.72% | Moxifloxacin (Standard) is the analytical standard of Moxifloxacin. This product is intended for research and analytical applications. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d4 hydrochloride | Moxifloxacin-d4 hydrochloride (BAY 12-8039-d4) is the hydrochloride salt form of deuterium labeled Moxifloxacin (Moxifloxacin). Moxifloxacin is an orally active antimicrobial, that can be used in the research of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d5 | Moxifloxacin-d5 (BAY 12-8039-d5 (free base)) is deuterium labeled Moxifloxacin. Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d3-1 hydrochloride | Moxifloxacin-d3-1 hydrochloride (BAY 12-8039-d3-1) is a deuterium labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-13C,d3 hydrochloride | 99.80% | Moxifloxacin-13C,d3 hydrochloride (BAY 12-8039-13C,d3) is 13C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin-d3 hydrochloride | Moxifloxacin-d3 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin hydrochloride is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Moxifloxacin | 99.75% | Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [Content Brief]
